pharma · Lymphoma · Primary immune thrombocytopenia (ITP)
Hutchison Medi Pharma
Hutchmed Europe B.V.
Hutchmed Europe is a pharma organization headquartered in EU. Primary therapeutic focus areas include Lymphoma, Primary immune thrombocytopenia (ITP). NovaPharmaNews links 4 clinical program(s), 0 drug profile(s), and 0
Company details
- Status
- Public
- HQ
- Shanghai, CN
- Employees
- 6
- Programs
- 4
- Drugs
- 6
- Patents
- 0
A Phase 1 Study of HMPL-306 in Locally Advanced Solid Tumors with IDH mutations
Phase 1 · other · - Locally advanced or metastatic solid tumors - Cholangiocarcinoma - Skeletal chondrosarcoma - Low-grade glioma - Any other solid tumor harboring an IDH mutation
A Phase 1 Study of HMPL-306 in Locally Advanced Solid Tumors with IDH mutations for - Locally advanced or metastatic solid tumors - Cholangiocarcinoma - Skeletal chondrosarcoma - Low-grade glioma - Any other solid tumor harboring an IDH mutation is a Phase 1 program (other) at Hutchmed Europe B.V. with 1 ClinicalTrials.gov record(s).
Internal code 2020-306-GLOB2
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Hutchmed Europe B.V.
- Phase
- Phase 1
- Modality
- other
- Indication
- - Locally advanced or metastatic solid tumors - Cholangiocarcinoma - Skeletal chondrosarcoma - Low-grade glioma - Any other solid tumor harboring an IDH mutation
- Status
- active
- Trials
- 1